



**SDI Review Form 1.6**

Journal Name:	<b><u>British Journal of Medicine and Medical Research</u></b>
Manuscript Number:	<b>Ms_BJMMR_20784</b>
Title of the Manuscript:	<b>A pilot, randomized sham control trial of autologous bone marrow stem cells in acute ischemic central retinal vein occlusion (sic study)</b>
Type of the Article	<b>Short communication</b>

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



**SDI Review Form 1.6**

**PART 1: Review Comments**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	<p><b>Results:</b></p> <ol style="list-style-type: none"> <li>1. Author should present the follow up results of those patients. [Visual acuity, intraocular pressure, slit lamp examination results in each follow up].</li> <li>2. The patient's response (local or systemic reaction) after injection of bone marrow stem cell should be presented.</li> </ol> <p><b>Discussion</b></p> <ol style="list-style-type: none"> <li>1. Whether case 2 have best results is related to early injection of bone marrow stem cell need further discussion.</li> <li>2. Whether the effect in the intervention group is related to the injection of triamcinolone acetonide need discussion.</li> </ol>	<p>Dear reviewer, thank you for contributing to the review of our manuscript.</p> <p>Results section:</p> <ol style="list-style-type: none"> <li>1. Base line and follow up visual acuity and slit lamp examination results had been already mentioned under each case. Intraocular pressure details for only case 3 were shown earlier. We have now added the intraocular pressure status to the other cases also.</li> <li>2. First patient had a central vitreous haze that cleared at the 4<sup>th</sup> week. Second patient had significant anterior chamber reaction that cleared by the 2<sup>nd</sup> week. This was mentioned in the initial submission but is now highlighted in yellow.</li> </ol> <p>Discussion section:</p> <ol style="list-style-type: none"> <li>1. Two further references have been added (reference number 14 and 15) to support this observation in our patient.</li> <li>2. The purpose of using 0.01mL triamcinolone along with 0.09mL</li> </ol>



**SDI Review Form 1.6**

		<p>was to suppress possible severe reaction to injection of autologous stem cells (which has been observed in some other studies with stem cells conducted at our centre by other authors-unpublished data). While it is true that some of the effect seen may be due triamcinolone, there is no literature that has actually studied the effect of such suboptimal doses of triamcinolone of any ocular pathology. Hence, we have already indicated this as a possible limiting factor in our discussion.</p>
<b><u>Minor</u></b> REVISION comments	<b>Much abbreviation in the manuscript. Full term for those abbreviations is needed.</b>	Full terms for all the abbreviations have now been incorporated (highlighted in yellow) when they appear for the first time in the text.
<b><u>Optional/General</u></b> comments	The authors investigate the effect of bone marrow stem cell injection on central retinal vein occlusion. It is valuable and interesting study. Because only 2 patients received bone marrow stem cell injection, the result shows the intervention group had better response. However; the better response in intervention group is related to bone marrow stem cell or triamcinolone acetamide is uncertain. The result may encourage physician to perform further large scale study.	<p>Please see response under discussion section (2) above.</p> <p>Thank you for the encouraging words. Yes, we are already in the process of obtaining financial support for a larger study.</p>